AI Article Synopsis
- This study investigates the increasing rates of cervical cancer among women aged 35 and younger over the past 30 years.
- The analysis involved 6257 patients and revealed that the incidence of cervical cancer in this age group rose from 2.8% to 15.7%, with adenocarcinoma cases also increasing significantly.
- The research highlights the importance of regular screening for cervical cancer in younger women, as a larger percentage of diagnosed cases in this group were found through routine cytological screening compared to older women.
Article Abstract
Aims: This study was performed to determine whether the incidence of cervical cancer in women aged 35 or younger has changed for the past 30 years and to examine the clinical characteristics of the cases.
Methods: The clinical and pathological data of 6257 patients with cervical cancer treated between January 1975 and December 2009 were retrospectively analyzed.
Results: The prevalence of young (≤ 35 years old) patients steadily increased from 2.8% to 15.7% for the past 30 years. The ratio of adenocarcinoma also rose from 1975-1979 to 2005-2009. In an analysis by age group, in group A, adenocarcinoma was found in 17% (≤ 35 years old); in group B, 7.1% (> 35 years old) [χ² = 78.92, P < 0.0001]. The clinical presentation presented showed that 36.4% of patients presented mainly postcoital bleeding in group A, whereas the symptom of irregular genital bleeding predominated in group B (P < 0.0001). The patients detected by routine cytological screening in group A (8.7%) were more than the patients in group B (3%).
Conclusions: The prevalence of cervical cancer in young women has been increasing steadily in Hubei, China. It is necessary for all sexually active women and women aged 35 years or even younger to undergo cervical cancer screening.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/igc.0b013e3181ecec79 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rare cancer survivorship research funding at the National Institutes of Health (NIH), 2017 to 2023.
Cancer Causes Control
January 2025
Office of Cancer Survivorship, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA.
Purpose: Rare cancers are defined as those for which there are less than 15 cases per 100,000 in the population annually. While much progress in detection and treatment has been made over the past decade for many rare cancers, less progress has been made in understanding survivorship needs. The objective of this study was to characterize the National Institutes of Health (NIH) cancer survivorship grant portfolio focused on rare cancers and to identify gaps specific to this area of science.
View Article and Find Full Text PDFHigh unmet needs for cervical cancer screening among women living with HIV in six African countries: A population-based study.
Int J STD AIDS
January 2025
Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
Background: Cisgender women living with HIV (WLWH) are disproportionately impacted by cervical cancer. Nevertheless, disparities in uptake and implementation of cervical cancer services persist in sub-Saharan Africa, where population-level estimates of screening coverage remain scarce.
Methods: We pooled data from nationally representative Population-based HIV Impact Assessment (PHIA) surveys conducted in Ethiopia, Malawi, Rwanda, Tanzania, Zambia, and Zimbabwe (2015-2019).
Incredible use of plant-derived bioactives as anticancer agents.
RSC Adv
January 2025
Department of Pharmaceutical Sciences, Maharshi Dayanand University Rohtak 124001 India
Cancer is a major global concern. Despite considerable advancements in cancer therapy and control, there are still large gaps and requirements for development. In recent years, various naturally occurring anticancer drugs have been derived from natural resources, such as alkaloids, glycosides, terpenes, terpenoids, flavones, and polyphenols.
View Article and Find Full Text PDFAn Unexpected Case of Clear Cell Adenocarcinoma of the Cervix in a Non-Diethylstilbestrol-Exposed Postmenopausal Woman.
Cureus
December 2024
Department of Family Medicine, Corewell Health Beaumont Grosse Pointe Hospital, Roseville, USA.
Clear cell adenocarcinoma of the cervix (CCAC) is a rare subtype of cervical adenocarcinoma. It has been linked to intrauterine exposure to diethylstilbestrol (DES) but can happen in non-DES-exposed patients, albeit less commonly. Presentation is largely vaginal bleeding, emphasizing the importance of considering CCAC in the differential of abnormal vaginal bleeding despite the tumor's rarity.
View Article and Find Full Text PDFKnowledge, Attitudes, and Perceptions of African Parents in New Zealand Towards the Human Papillomavirus Vaccine.
Cureus
December 2024
Research, Oceania University of Medicine, Apia, WSM.
Introduction Human papillomavirus (HPV) is a well-documented cause of cervical cancer, leading to significant mortality that may be decreased through screening and the administration of HPV vaccination. Our understanding of New Zealand immigrants' knowledge, attitudes, and perceptions of the HPV vaccine is limited. Preliminary research shows that immigrants have low knowledge and negative perceptions of the HPV vaccine and that cervical cancer and HPV awareness was low among African parents.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!